Continue to Submission Form

In just a few easy steps, submit your innovation.

CSL logos

Welcome to CSL’s Open Innovation Submission Portal

CSL is a leading global biotech company that develops and delivers innovative biotherapies that help people with life-threatening medical conditions live full lives. Innovation has been in CSL's DNA for more than a century. CSL has the full spectrum of strengths from research and clinical development to manufacturing and commercialization across six therapeutic areas of expertise. Our strengths enable us to accurately identify, successfully develop, and dependably deliver innovations for patients.

At CSL we believe that for innovation to be fast tracked, we need to partner with the brightest minds in the sector. We know that partnerships can accelerate innovation and delivery of new life-saving and protective medicines and we collaborate and work with external organizations that have unique technologies, assets and equipment, to address patients' unmet needs around the globe.

If you have an idea related to new products, new technologies or new advancements relating to CSL's areas of interest, please feel free to share it via the Submission Form. All submissions will be screened by yet2 and if successful, will be shared with CSL. Initial submissions should not include any confidential information.

Focus Areas

CSL is seeking new ideas in the these focus areas. Please click on the links below to find out more about these areas and our current interests.

CSL's mission is to discover, develop and deliver our innovative therapies that improve the patients' quality of life while maintaining the highest product safety standards and continually improving manufacturing effectiveness. We know that partnerships can accelerate innovation and delivery of new unique technologies, assets, and equipment, to address patients’ unmet needs around the globe. Below you will find our current interest areas where we seek innovative ideas that can improve our processes, equipment, and analytical capabilities within our three strategic scientific platforms of plasma fractionation, recombinant protein technology, and cell and gene therapies.



Click on the buttons below to learn more:

Core interests for early stage partnering

  • Cell & Gene Therapy
    • Gene editing / genomics
      1. Improve insertional editing efficiencies in vivo
      2. Genetic elements enhancing regulation of cells of the immune system (e.g., promoters and enhancers)
    • In vivo Delivery
      1. Delivering nucleic acid templates for insertional gene editing
      2. Targeting moiety for HSCs
    • GT safety
      • Technologies that minimize SAEs from insertional gene editing
    • Areas not of interest
      • Oncology (including hematological malignancies)
      • Ex vivo cell therapy
  • Plasma Protein Research
    • Novel plasma therapeutic candidates
      1. All diseases considered. Candidates aligned with CSL’s therapeutic areas will be prioritized
      2. CSL can provide native human plasma proteins (≥ μg/L plasma concentration) for preclinical proof-of-concept studies
    • Novel association of plasma protein function with disease
      1. Basedon healthy and patient clinical data sets, or
      2. Access to patient data sets with corresponding clinical data to enable association studies to be performed
    • Novel methods for plasma protein purification
      • Protein purification systems capable of targeted purification from plasma with high purity at research scale (methods translatable to manufacturing scale will be prioritized)